Markets:

Overview

News

Currencies

International

Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

8.130 +0.070 (+0.87%)

Streaming Delayed Price Updated: 2:46 PM EDT, Jul 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Atara Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Small-Cap Renaissance: Russell 2000 Scales New Heights While Big Tech Stumbles

January 08, 2026

In a dramatic shift that has recalibrated the pulse of Wall Street, the Russell 2000 index (RUT) surged to a new record high on January 8, 2026, signaling a definitive breakout for small-cap stocks. As...

Via MarketMinute

Small-Cap Slump: Russell 2000 Tumbles as Sticky Inflation Data Revives 'Higher-for-Longer' Fears

January 07, 2026

The Russell 2000 index, the primary benchmark for American small-cap stocks, suffered a significant sell-off on Wednesday, January 7, 2026, as a batch of conflicting economic data sparked fears that...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

November 12, 2025

From Atara Biotherapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 17, 2025

Via Benzinga

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗

September 29, 2025

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.

Via Benzinga

Atara Biotherapeutics Announces Changes to Its Board of Directors

September 03, 2025

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

August 11, 2025

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

July 24, 2025

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

July 14, 2025

From Atara Biotherapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

June 18, 2025

Via Benzinga

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

May 16, 2025

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

May 15, 2025

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Announces Pricing of $16 Million Offering

May 15, 2025

From Atara Biotherapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 06, 2025

Via Benzinga

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

May 05, 2025

From Atara Biotherapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 24, 2025

Via Benzinga

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

March 07, 2025

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 07, 2025

From Atara Biotherapeutics, Inc.

Via Business Wire

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

January 27, 2025

From The Schall Law Firm

Via Business Wire

FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs ↗

January 21, 2025

FDA halts Atara's EBVALLO and ATA3219 trials over manufacturing issues. Atara eyes $60 million milestone from Pierre Fabre upon EBVALLO approval.

Via Benzinga

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

January 21, 2025

From Atara Biotherapeutics, Inc.

Via Business Wire

Nasdaq Down 150 Points; Morgan Stanley Earnings Top Estimates ↗

January 16, 2025

Via Benzinga

Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip ↗

January 16, 2025

CEO Cokey Nguyen expressed confidence in resolving the issue, expecting resubmission and potential approval within six months of addressing the manufacturing compliance concerns.

Via Stocktwits

Crude Oil Down 1%; Bank of America Posts Upbeat Earnings ↗

January 16, 2025

Via Benzinga

US Stocks Edge Lower; Retail Sales Increase Less Than Expected ↗

January 16, 2025

Via Benzinga

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

January 16, 2025

From Atara Biotherapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

January 14, 2025

Via Benzinga

Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference

November 27, 2024

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference

November 13, 2024

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress

November 12, 2024

From Atara Biotherapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.